Overview
- The White House Council of Economic Advisers, in a report released Tuesday, projected $529 billion in 10‑year savings from tying U.S. drug launch prices to those in other wealthy nations.
- The administration says 17 major manufacturers have signed voluntary most‑favored‑nation agreements that set comparable prices for new U.S. drugs.
- The report estimates $64.3 billion in combined federal and state Medicaid savings over a decade by making existing drugs available to Medicaid at MFN prices.
- Officials highlight direct cash discounts via TrumpRx.gov, saying uninsured users of GLP‑1 weight‑loss drugs could save about $3,000 a year, which they say supports broader Medicare coverage of obesity treatments.
- Democratic senators and outside analysts press for full disclosure of the confidential deals and note the CBO’s 2024 estimate of only modest, potentially fading price cuts under similar policies.